# TRANSCRIPT — R-CLIN-B
model: gpt-5.5-2026-04-23 | reasoning_effort: high | retrieval: full-read | web: DISABLED (no hosted tools) | started: 2026-06-03T22:00:52
docs available: ['INDEX', 'proof', 'ref01', 'ref02', 'ref03', 'ref04', 'ref06', 'ref07', 'ref08', 'ref09', 'ref10', 'ref11', 'ref12', 'ref13', 'ref14', 'ref15', 'ref17', 'ref18', 'ref19', 'ref20', 'ref21', 'ref22', 'ref23', 'ref24']

===== DEVELOPER MESSAGE =====
You are running inside an OFFLINE evaluation harness. You have NO internet access and NO shell. Access documents ONLY through these tools:
- list_docs(): list available document names.
- search_doc(name, query): find passages matching a query (regex/text) with surrounding context.
- read_doc(name, offset, length): read a document, optionally a bounded window.
- write_note(name, content): optional scratch memory.
Documents: 'proof' (the submitted manuscript proof, including its bound supplementary appendix), 'INDEX' (maps each cited reference number to its source), and 'ref01'..'ref24' (full text of each cited reference). References 5 and 16 are NOT provided (no ref05/ref16). When the instructions refer to the manuscript PDF, 'pdfs/INDEX.md', or a reference's PDF, use the matching name (reference 7 -> 'ref07').

Read whatever you need (read_doc returns whole documents by default), then produce your review.

===== USER INSTRUCTION (verbatim) =====
You are serving as a peer reviewer for a general medical journal (the BMJ tier). You have been sent a manuscript reporting a randomized controlled trial and PDFs of the references it cites. You do not have the raw data or the analysis code — review what you have been given, as a reviewer at submission would. Your job is to produce a rigorous, fair, and specific peer-review report that helps the editors decide whether the work is sound and what revisions it needs.

You have no internet access. You are reviewing this manuscript pre-publication; treat the trial's results elsewhere, this paper, and any outside commentary as unavailable. The references the manuscript cites are provided as PDFs in `pdfs/` (an index maps each to its reference number) — consult those directly rather than relying on memory when you need to check what a cited source says.

Ground every point in the manuscript or a cited reference. Do not raise generic concerns you cannot tie to something specific in these materials. Distinguish issues that are major (could change conclusions or require new analysis) from minor (clarity, reporting). Be concrete: cite sections, tables, figures, page numbers, and the specific sentence at issue.

Produce your report in the format specified at the end of these instructions.

## Your role

Your focus is interpretability, applicability, and safety as a general reader and as an editor would weigh them: is the primary outcome clinically meaningful and clearly defined; is the trial adequately powered for the safety and hard outcomes it comments on, or only for its primary endpoint; how generalizable are the results given the trial's setting and population; and is the reporting balanced (do the abstract and conclusions match the results). Flag any place the manuscript's framing outruns its evidence.

## Your materials

You have been given exactly these, and nothing else (no internet, no raw data, no analysis code, no published version of this paper, no other commentary):

1. **The submitted manuscript proof** — `inputs/27_jan_2026_bmj-2026-089636_proof_hi.pdf`. This is the complete submission. It **includes the supplementary appendix** bound at the end (table of contents plus supplementary tables S1–S14, the per-protocol population detail, supplementary figures, and a pointer to the trial's pre-specified protocol and statistical analysis plan).
2. **The cited references** — the manuscript cites 24 references; their PDFs are in `pdfs/`, mapped reference-number → file in `pdfs/INDEX.md`. **22 of the 24 are present.** Two are unavailable: reference 5 and reference 16. For any point that would rest on one of those two sources, state that you could not check it because the source was not provided, rather than relying on memory.

## Required output format

End your review with these sections, in this order:

1. **Summary** (3–5 sentences: what the trial did, your overall assessment).
2. **Major points** (numbered; each with the specific manuscript/reference location).
3. **Minor points** (numbered).
4. **Anything you verified that checked out** (numbered; what you confirmed against a cited source — so editors know what was checked, not just what failed).
5. **Editorial recommendation** (accept / minor revision / major revision / reject) **with one paragraph of justification.**
6. **What I could not assess** (limits of what you could check with the materials given — e.g., anything needing the raw data).

===== FINAL OUTPUT =====
## 1. Summary

This multicentre, double blind, placebo controlled trial randomised 1732 pregnant women with placenta praevia/low-lying placenta undergoing caesarean delivery in 24 Chinese maternity units to tranexamic acid or placebo after cord clamping, in addition to prophylactic oxytocin. The reported primary outcome—calculated estimated blood loss ≥1000 mL or red cell transfusion within 2 days—was lower with tranexamic acid: 29.7% v 35.1%, relative risk 0.83, 95.2% CI 0.73 to 0.94. The trial addresses an important high-risk population and has strong features, including randomisation, blinding, high primary-outcome completeness, and a prespecified primary endpoint. However, the manuscript needs major revision before publication because the conclusions and abstract overstate what can be inferred about clinical benefit and safety, the protocol/SAP history and post hoc PAS reclassification require much clearer reporting, and several tabled effect estimates appear internally inconsistent.

## 2. Major points

1. **Protocol/SAP versioning and post hoc changes need transparent reporting**  
   - **Location:** Methods, “Study design,” manuscript p 6–7, lines 168–180; supplementary protocol, p 49–53 of proof; SAP, p 77–82 and p 87–91 of proof.  
   - The manuscript states that the protocol was approved on 30 May 2023 and that the authors attest to “fidelity of the trial to the protocol and statistical analysis plan” (p 7, lines 172–180). However, the bound protocol is **Version 7.0 dated 16 Dec 2025**, after the stated trial period of July 2023–March 2025, and the version history says that between October and December 2025, “in response to peer-review feedback,” PAS diagnosis was re-evaluated, changing the PAS rate from 39.0% to 17.9% (supplementary protocol p 53). The SAP is Version 3.0 dated 1 June 2024 but references protocol Version 7.0 dated 16 Dec 2025 (SAP p 77), and the SAP revision history states that post hoc sensitivity analyses and the per-protocol definition were added during the trial (SAP p 80–82).  
   - This does not necessarily undermine the primary analysis, which appears consistent with the published protocol (ref 12), but it is not currently transparent enough for readers to distinguish what was finalised before recruitment, before interim analysis, before database lock, before unblinding, and after outcome knowledge.  
   - **Required revision:** Provide a protocol/SAP chronology table with version dates, dates of ethics approval, recruitment status at each change, whether investigators/statisticians were blinded, date of database lock, date of unblinding, and which analyses/outcomes were prespecified versus post hoc. Ideally include the originally approved protocol/SAP or a tracked-changes supplement. The wording about “fidelity” should be qualified if the submitted protocol is a post-trial version.

2. **PAS classification is important to interpretation but the adjudication process is inconsistent across sections**  
   - **Location:** Participants, manuscript p 8, lines 190–196; Table 1; supplementary Table S1; protocol version history p 53.  
   - The manuscript says that “two senior obstetricians independently reviewed the surgical records and pathology reports post hoc for all cases” (p 8, lines 194–196). Supplementary Table S1 says they screened “surgical records and pathology reports of PAS cases.” The protocol version history is more specific: initially 661/1694 were identified as PAS from inpatient face sheets; surgical/pathology reports “for all 661 patients initially identified with PAS” were reviewed; 303 were confirmed and 358 were deemed overdiagnoses (p 53). This leaves unclear whether records for women initially classified as non-PAS were reviewed to detect false negatives.  
   - Because PAS is used for baseline description, subgroup analysis, and the discussion of generalisability (303/1694, 17.9%), this matters. Ref 15 itself emphasises that PAS diagnosis is vulnerable to overdiagnosis and heterogeneity when clinical criteria are used.  
   - **Required revision:** Clarify the PAS adjudication denominator: were all 1694 cases reviewed, or only the 661 initially labelled PAS? Were adjudicators blinded to trial group and outcomes? Provide a PAS adjudication flow diagram showing initial classification, records available, histological confirmation, clinical confirmation, overdiagnosis, and any assessment of false negatives. If only initially positive cases were reviewed, revise statements that imply all cases were adjudicated.

3. **The primary outcome is statistically positive, but the manuscript should be clearer about clinical meaning and hard outcomes**  
   - **Location:** Abstract Results/Conclusions, p 5, lines 125–131; Outcomes, p 8–9, lines 242–253; Table 2; Discussion, p 12–13, lines 379–399 and p 14, lines 420–423.  
   - The primary outcome was a composite of calculated estimated blood loss ≥1000 mL or red cell transfusion within 2 days. The absolute reduction was 5.4 percentage points, NNT 19. However, several more clinically direct outcomes were not reduced: hysterectomy 2.2% v 2.1%, hypovolaemic shock 0.9% v 0.9%, ICU/HDU transfer 13.4% v 13.5%, additional operations 58.3% v 58.0%, open-label tranexamic acid 11.6% v 12.1%, and hospital stay 7 v 7 days (Table 2).  
   - This is particularly important because ref 10 notes that postpartum blood-loss thresholds have uncertain clinical relevance and that blood loss is difficult to measure accurately; ref 7 similarly found a reduction in calculated blood loss/transfusion but not in several haemorrhage-related clinical secondary outcomes.  
   - **Required revision:** Reframe the abstract and discussion to specify that tranexamic acid reduced the prespecified composite of calculated blood loss and early transfusion, but the trial did not show reductions in severe morbidity, hysterectomy, shock, ICU/HDU transfer, or hospital stay. The conclusion “reduced postpartum haemorrhage” is acceptable only if immediately tied to the trial’s operational definition.

4. **Safety conclusions are too strong for the number of events and the selected population**  
   - **Location:** Abstract, p 5, lines 127–131; Adverse events, p 12–13, lines 349–355; Table 3; supplementary Table S12; Discussion, p 13, lines 400–408.  
   - The abstract says tranexamic acid reduced postpartum haemorrhage “without increasing serious adverse events.” But serious adverse events were very rare: 4/837 v 4/845, RR 1.01, 95% CI 0.25 to 4.01. This confidence interval is compatible with substantial harm or benefit. The trial also excluded women with thromboembolic risk factors, thrombophilia, recent LMWH/antiplatelet use, severe coagulopathy, active cardiovascular/renal/liver disease, autoimmune disease, eclampsia/HELLP, abruption, fetal death, haemoglobin ≤9 g/dL, and estimated blood loss >500 mL within 12 hours before caesarean (Table S2).  
   - Ref 9 concludes that evidence for serious adverse events such as thromboembolism is very uncertain, and ref 10 states that a modest increase in thrombosis cannot be excluded.  
   - **Required revision:** Replace “without increasing serious adverse events” with “no increase in serious adverse events was observed, but the trial was not powered to exclude clinically important differences in rare harms.” This caveat should appear in the abstract and conclusion. Also explain the missingness in day-2 laboratory safety data in Table S12.

5. **Several tabled estimates appear internally inconsistent and require audit before publication**  
   - **Location:** Table 2, Table 3, supplementary Tables S11 and S12.  
   - Examples:  
     - Table 2: gravimetrically estimated blood loss is 790 mL v 813 mL, but the mean difference is printed as –24.70 with CI “–41.30 to 90.70,” which is not centred on the estimate and appears sign-inconsistent.  
     - Table 2: transfusion by discharge is 164/845 v 185/849, but the RR is reported as 0.85 with an implausibly narrow 95% CI of 0.85 to 0.86.  
     - Table 2: ICU/HDU transfer is 113/845 v 115/849, but the RR is reported as 1.03, 95% CI 0.98 to 1.08, which seems inconsistent with the crude rates and likely too narrow.  
     - Table S11: uterotonic use is 774/831 v 798/844, but the RR is reported as 0.76; ICU/HDU transfer is 111/831 v 115/844, but the RR is reported as 0.83.  
     - Table S12: alanine transaminase >2×ULN is reported as 9 (1.4%) v 71 (1.1%), which is mathematically impossible unless “71” is a typographical error.  
   - These errors affect interpretation of secondary and safety outcomes and reduce confidence in the tables.  
   - **Required revision:** Audit all tables against the statistical output and raw denominators; correct point estimates, confidence intervals, denominators, and signs; and provide a statement that the tables have been independently checked.

6. **Modified intention-to-treat exclusions after randomisation should be labelled and explored**  
   - **Location:** Statistical analysis, p 10, lines 281–284; Results, p 11, lines 311–315; Figure 1; Table S7.  
   - The manuscript calls the main analysis ITT but excludes 38 randomised women before delivery: 25 in the tranexamic acid arm and 13 in the placebo arm. Reasons include withdrawal before drug administration, caesarean delivery before 34 weeks, preoperative Hb <9 g/dL, and thalassaemia (Table S7). A further three placebo participants had missing primary outcome data.  
   - Excluding randomised participants is sometimes unavoidable, especially after withdrawal of consent, but it should be described as a modified ITT analysis. The differential exclusion count is small relative to the trial size but should be addressed.  
   - **Required revision:** Rename the analysis population as modified ITT unless all randomised participants were truly included. Provide sensitivity analyses for the primary outcome under conservative assumptions for missing primary outcome data and, where ethically/statutorily possible, post-randomisation exclusions. At minimum, discuss why differential exclusions are unlikely to explain the result.

7. **Generalisability should be more explicit in the abstract and discussion**  
   - **Location:** Participants, p 7–8, lines 182–204; Table S2; Limitations, p 13–14, lines 410–418; Discussion of Chinese PAS management, p 12, lines 367–378.  
   - This trial was conducted in 24 Chinese maternity units, many tertiary/high-risk referral centres. The trial excluded several groups commonly relevant to placenta praevia care: haemoglobin ≤9 g/dL, estimated blood loss >500 mL in the preceding 12 hours, thromboembolic risk factors, recent anticoagulant/antiplatelet use, active cardiovascular/renal/hepatic disease, severe coagulopathy, eclampsia/HELLP, abruption, and fetal death. The authors also state that comprehensive screening/exclusion data were not feasible (p 13, lines 410–413).  
   - The discussion acknowledges national practice differences, including low hysterectomy and frequent partial myometrial resection, but the abstract simply says “pregnant women with placenta praevia.”  
   - **Required revision:** In the abstract and conclusion, specify “eligible women at Chinese maternity units” and avoid implying applicability to women with severe anaemia, ongoing antepartum bleeding, high thrombotic risk, or settings with different PAS/hysterectomy practices. If any screening logs exist, provide the number screened, eligible, excluded by reason, and enrolled, ideally by centre.

8. **The transfusion component of the primary outcome needs more detail**  
   - **Location:** Outcomes, p 8–9, lines 242–248; Table S4; Table 2 notes.  
   - Red cell transfusion within 2 days is part of the primary endpoint, but transfusion practice was guided by “comprehensive assessment” with thresholds varying according to active haemorrhage and haemodynamic instability (Table S4). This is clinically appropriate but can introduce centre-level variation. Randomisation and blinding mitigate this, but the manuscript should show that transfusion criteria and blood availability were consistent enough across sites.  
   - Also, for participants transfused before day-2 blood sampling, Table 2 explains imputation for haemoglobin/haematocrit secondary outcomes, but the Outcomes section is less explicit about how calculated estimated blood loss was handled in transfused participants.  
   - **Required revision:** Clarify exactly how postoperative haematocrit and calculated estimated blood loss were derived in participants transfused before laboratory sampling. Consider reporting centre-level transfusion rates or a sensitivity analysis for the primary outcome excluding the transfusion component, which is partly provided as “calculated estimated blood loss ≥1000 mL” but should be emphasised.

## 3. Minor points

1. **Reference 1 title should be corrected.** The manuscript cites “Roadmap for the prevention and management of postpartum haemorrhage (PPH),” but the provided WHO document is titled *A Roadmap to combat postpartum haemorrhage between 2023 and 2030*.

2. **Reference 5 was not provided.** The statement that placenta praevia prevalence has been increasing “in many countries” (Introduction, p 6, line 151) depends partly on ref 5, which I could not check. Either provide the source or support the claim with an available reference.

3. **Reference 16 was not provided.** The claim that surgical procedures adhered to Chinese guidelines (p 8, lines 232–235) relies on ref 16, which I could not verify. Given the importance of surgical standardisation, please describe the key operative and transfusion principles in the supplement rather than relying on an unavailable source.

4. **Clarify terminology: placenta praevia versus low-lying placenta.** About 26% of participants had low-lying placenta (Table 1). This is clear in Methods but less clear in the title/abstract. Consider “placenta praevia or low-lying placenta” in the abstract Participants sentence.

5. **Figure 2 subgroup reporting needs interaction tests and event counts.** The text says there was no significant variation across subgroups (p 11, lines 332–335), but the figure legend does not mention interaction P values. Please provide event counts, RRs, CIs, and interaction P values, while noting limited power.

6. **“Transfer to intensive care unit” includes obstetric high-dependency unit.** Table 2 note explains this, but the main text should call it “ICU or obstetric high-dependency unit” to avoid overstating ICU use.

7. **Baseline significance testing is unnecessary.** Table S8 provides P values for baseline variables; CONSORT generally discourages hypothesis testing for baseline imbalance. Consider removing or moving these to a supplement with an explanation that they were descriptive.

8. **Report actual body weight, not only BMI, if body weight is central to calculated blood loss.** The discussion attributes differences from TRAAP2 partly to body weight/BMI (p 13, lines 384–391), and the formula uses body weight ×85. Please provide mean/median delivery weight by group and clarify whether BMI is prepregnancy or at delivery.

9. **Adverse-event ascertainment in the operating room seems unusually low.** Nausea/vomiting was 1.3% v 1.2% (Table 3), and the discussion acknowledges possible underreporting (p 13, line 405). Please describe how actively symptoms were solicited and whether anaesthesia type affected reporting.

10. **Typos and formatting issues in the supplement should be corrected.** Examples include “TableS 9,” “Defination,” “cancealment,” “Blingding,” “requring,” “confidencial,” and “umbilical-cord lamping.”

11. **Trial registration date discrepancy.** The manuscript gives ClinicalTrials.gov NCT05811676 but no registration date; ref 12 reports March 15, 2023, whereas the supplement checklist reports March 31, 2023. Please reconcile.

12. **Data sharing statement is restrictive.** It states that data are available for academic purposes with approved proposals to TRAPP investigators. For a BMJ-tier journal, consider whether the statistical code and a data dictionary can also be shared.

## 4. Anything you verified that checked out

1. **Global importance of PPH:** The WHO roadmap (ref 1) supports the manuscript’s statement that PPH accounts for over 20% of maternal deaths globally.

2. **China placenta praevia prevalence trend:** Ref 6 supports the statement that prevalence increased after the two-child policy; it reports an increase from 1.25% to 4.12%.

3. **Placenta praevia/low-lying definition:** Ref 3 supports classifying placenta previa as covering the cervical os and low-lying placenta as placental edge ≤20 mm from the os.

4. **TRAAP2 comparison:** Ref 7 used a very similar primary endpoint—calculated estimated blood loss >1000 mL or red-cell transfusion by day 2—and reported 26.7% v 31.6% with tranexamic acid versus placebo, with no significant reductions in several clinical secondary outcomes.

5. **US caesarean trial comparison:** Ref 8 supports the manuscript’s statement that tranexamic acid did not significantly reduce the composite of maternal death or transfusion and that postpartum infections were higher in the tranexamic acid group: 3.2% v 2.5%, RR 1.28, 95% CI 1.02 to 1.61.

6. **Need for evidence in high-risk groups:** Ref 9 supports the rationale that most prophylactic caesarean TXA evidence came from low-risk/high-resource settings and that evidence for thromboembolic events and other rare serious harms remains very uncertain.

7. **PAS diagnostic criteria:** Supplementary Table S1 closely tracks the FIGO clinical/histological classification in ref 15.

8. **Calculated versus measured blood loss discrepancy:** Ref 24 supports the authors’ discussion that calculated blood loss and quantitative/gravimetric blood loss can differ substantially and correlate only moderately.

## 5. Editorial recommendation

**Major revision.** The trial addresses an important clinical question and the primary result is potentially publishable, but the manuscript in its current form is not yet ready for a general medical journal. The main concerns are not primarily about the randomised design itself; rather, they are about transparency of post-trial protocol/SAP changes, the post hoc PAS reclassification, overstatement of safety and clinical benefit, limited generalisability to the highest-risk placenta praevia patients, and multiple internally inconsistent table entries. These issues are correctable, but they require a substantive revision, careful statistical/table audit, and more cautious interpretation.

## 6. What I could not assess

1. I did not have access to raw participant-level data or statistical code, so I could not reproduce the primary or secondary analyses.

2. I could not verify the ClinicalTrials.gov record or the timing/content of registry changes because no internet access was available.

3. I could not assess the original approved protocol/SAP unless contained in the proof; the bound protocol is a later version dated after trial completion.

4. I could not determine whether PAS adjudicators were blinded to treatment/outcomes or whether all non-PAS cases were reviewed without access to adjudication records.

5. I could not assess screening denominators, reasons for all non-enrolment, or centre-level enrolment/transfusion/surgical practice variation beyond what is reported.

6. I could not verify claims resting on reference 5 or reference 16 because those PDFs were not provided.

7. I could not assess DSMB deliberations, interim analysis results, or adverse-event adjudication beyond the summary reporting in the manuscript.

===== TOKENS =====
api_calls=40  input=3660508 (cached=3488768)  output=11515  (reasoning=5469)  total=3672023
est_cost: $2.95 (cached@$0.50/M) .. $18.65 (upper bound) | dashboard authoritative

===== END (2026-06-03T22:06:21) =====